Abtak Logo

wockhardt News

Stay updated with the latest wockhardt news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on wockhardt topics.

Abtak.com - Business - News Image
soure image
16
BusinessDec 01, 2025 07:07 PM

Mahindra Records 19 Per Cent YoY Growth In Nov'25; Car Sales Up By 22 Per Cent

Mahindra & Mahindra on Monday said its total sales increased 19 per cent year-on-year to 92,670 units in November. In the passenger vehicle segment, the company sold 56,336 vehicles in the domestic market, a growth of 22 per cent over 46,222 units in the year-ago period, Mahindra & Mahindra (M&M) said in a statement. The domestic sales for commercial vehicles stood at 24,843, a growth of 17 per cent year-on-year, it added. Mahindra & Mahindra's Farm Equipment Business reported sales of 42,273 t ...Read More >

Abtak.com - Business - News Image
soure image
17
BusinessSep 29, 2025 08:09 AM

Smallcaps tumble up to 77% as broader indices lag

For the month, FII sold equities worth Rs 30,141.68 crore, while DII bought equities worth Rs 55,736.09 crore. The broader indices broke a three-week gaining streak and underperformed the main indices as markets remained under pressure throughout the week on worries over fresh tariffs on pharma, higher visa fees by the US, persistent trade concerns, and continued FII selling. For the week, Nifty50 plunged 672.35 points or 2.65 percent to finish at 24,654.70, while the BSE Sensex index declined ...Read More >

The Hans India - Business - News Image
soure image
32
BusinessSep 27, 2025 10:19 AM

Trump tariffs on drugs triggers sell-off in markets

Mumbai: Benchmark stock indices Sensex and Nifty tumbled nearly one per cent on Friday, marking their sixth consecutive day of decline, following heavy selling in pharma and IT shares as US President Donald Trump announced 100 per cent duties on branded drugs from next month. The 30-share BSE Sensex tanked 733.22 points or 0.90 per cent to settle at a three-week low of 80,426.46. During the day, it dropped 827.27 points or one per cent to 80,332.41 points. The 50-share NSE Nifty tumbled 236.15 p ...Read More >

NewsDrum - Business - News Image
soure image
22
BusinessSep 26, 2025 04:37 PM

Sensex, Nifty tank nearly 1 pc on selling in pharma, IT shares after new Trump tariffs on drugs

Mumbai, Sep 26 (PTI) Benchmark stock indices Sensex and Nifty tumbled nearly 1 per cent on Friday, marking their sixth consecutive day of decline, following heavy selling in pharma and IT shares as US President Donald Trump announced 100 per cent duties on pharmaceutical drugs from next month. The 30-share BSE Sensex tanked 733.22 points or 0.90 per cent to settle at a three-week low of 80,426.46. During the day, it dropped 827.27 points or 1 per cent to 80,332.41. The 50-share NSE Nifty tumbl ...Read More >

NewsDrum - Business - News Image
soure image
34
BusinessSep 26, 2025 11:01 AM

Pharma stocks decline; Wockhardt tumbles over 6 pc

New Delhi, Sep 26 (PTI) Pharma stocks fell in morning trade on Friday as investors grew concerned after US President Donald Trump announced import taxes of 100 per cent on branded and patented pharmaceutical drugs. Wockhardt Ltd tumbled 6.58 per cent, Natco Pharma tanked 5.46 per cent, Sun Pharma dropped 4.96 per cent, Indoco Remedies edged lower by 4.70 per cent, Glenmark Pharma fell by 2.88 per cent, Aurobindo Pharma 2.44 per cent and Dr Reddys dipped 2.31 per cent on the BSE. The BSE health ...Read More >

The Hans India - Other - News Image
soure image
1
OtherJun 06, 2025 09:09 AM

Wockhardt eyes $7 bn mkt opp for antibiotic Zaynich

New Delhi: Drugmaker Wockhardt said its novel antibiotic Zaynich has an addressable market opportunity of $7 billion in the US and Europe. The company said it has completed a pre-NDA (non-disclosure agreement) meeting with the US Food and Drug Administration (USFDA) in May 2025. Filing to the USFDA is slated in the second quarter of the current fiscal with potential launch in FY2026-27, Wockhardt Ltd said in a regulatory filing. The company plans for regulatory approval for the product in Europ ...Read More >

Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.